|
Rhabdomyosarcoma Global Clinical Trials Review, H1, 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 118 seiten | |||||||||
| Inhalt der Studie: |
Introduction
GlobalData's clinical trial report, “Rhabdomyosarcoma Global Clinical Trials Review, H1, 2012" provides data on the Rhabdomyosarcoma clinical trial scenario. This report provides element.....
Introduction GlobalData's clinical trial report, “Rhabdomyosarcoma Global Clinical Trials Review, H1, 2012" provides data on the Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rhabdomyosarcoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Highlights Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Rhabdomyosarcoma 6 Report Guidance 6 Clinical Trials by Region 7 Clinical Trials by Country 8 Top Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by BRIC Nations 14 Clinical Trials by G7 Nations 15 Clinical Trials in G7 Nations by Trial Status 16 Clinical Trials by E7 Nations 17 Clinical Trials in E7 Nations by Trial Status 18 Clinical Trials by Phase 19 In Progress Trials by Phase 20 Clinical Trials by Trial Status 21 Unaccomplished Trials of Rhabdomyosarcoma 22 Subjects Recruited Over a Period of Time 23 Prominent Sponsors 24 Top Companies Participating in Rhabdomyosarcoma Therapeutics Clinical Trials 26 Prominent Drug Comparison 27 Clinical Trial Profiles 28 Clinical Trial Overview of Top Companies 28 Jennerex Biotherapeutics, Inc. 28 Clinical Trial Overview of Jennerex Biotherapeutics, Inc. 28 Novartis AG 29 Clinical Trial Overview of Novartis AG 29 Daiichi Sankyo Company, Limited 30 Clinical Trial Overview of Daiichi Sankyo Company, Limited 30 Eli Lilly and Company 31 Clinical Trial Overview of Eli Lilly and Company 31 F. Hoffmann-La Roche Ltd. 32 Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 32 Clinical Trial Overview of Top Universities / Institutes / Hospitals 33 St. Jude Children’s Research Hospital, Inc. 33 Clinical Trial Overview of St. Jude Children’s Research Hospital, Inc. 33 Fred Hutchinson Cancer Research Center 34 Clinical Trial Overview of Fred Hutchinson Cancer Research Center 34 Children's Memorial Hospital 35 Clinical Trial Overview of Children's Memorial Hospital 35 Medical College of Wisconsin 36 Clinical Trial Overview of Medical College of Wisconsin 36 Hospital Santa Marcelina 37 Clinical Trial Overview of Hospital Santa Marcelina 37 European Paediatric Soft Tissue Sarcoma Study Group 38 Clinical Trial Overview of European Paediatric Soft Tissue Sarcoma Study Group 38 City of Hope National Medical Center 39 Clinical Trial Overview of City of Hope National Medical Center 39 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 40 Clinical Trial Overview of Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 40 Sarcoma Alliance for Research through Collaboration 41 Clinical Trial Overview of Sarcoma Alliance for Research through Collaboration 41 Centre Oscar Lambret 42 Clinical Trial Overview of Centre Oscar Lambret 42 Memorial Sloan Kettering Cancer Center 43 Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 43 Dana-Farber Cancer Institute 44 Clinical Trial Overview of Dana-Farber Cancer Institute 44 Emory University 45 Clinical Trial Overview of Emory University 45 University Hospital Basel 46 Clinical Trial Overview of University Hospital Basel 46 Stanford University 47 Clinical Trial Overview of Stanford University 47 Penn State University 48 Clinical Trial Overview of Penn State University 48 Massachusetts General Hospital 49 Clinical Trial Overview of Massachusetts General Hospital 49 Five Key Clinical Profiles 50 Appendix 116 Abbreviations 116 Definitions 116 Research Methodology 117 Secondary Research 117 About GlobalData 117 Contact Us 118 Disclaimer 118 Source 118 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Zone, 2012* 7 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 8 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 9 Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2012* 10 Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2012* 11 Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries, 2012* 12 Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2012* 13 Rhabdomyosarcoma Therapeutics Clinical Trials, BRIC Countries, 2012* 14 Rhabdomyosarcoma Therapeutics Clinical Trials, G7 Countries, 2012* 15 Rhabdomyosarcoma Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 16 Rhabdomyosarcoma Therapeutics Clinical Trials, E7 Countries, 2012* 17 Rhabdomyosarcoma Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 18 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Phase, 2012* 19 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012* 20 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 21 Rhabdomyosarcoma Therapeutics Market, Global, Withdrawn Clinical Trials, 2012* 22 Rhabdomyosarcoma Therapeutics Market, Global, Terminated Clinical Trials, 2012* 22 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010 23 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 25 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 26 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 27 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Jennerex Biotherapeutics, Inc., 2012* 28 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2012* 29 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2012* 30 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2012* 31 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2012* 32 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Jude Children’s Research Hospital, Inc., 2012* 33 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2012* 34 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Memorial Hospital, 2012* 35 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical College of Wisconsin, 2012* 36 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital Santa Marcelina, 2012* 37 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Paediatric Soft Tissue Sarcoma Study Group, 2012* 38 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope National Medical Center, 2012* 39 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, 2012* 40 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarcoma Alliance for Research through Collaboration, 2012* 41 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Oscar Lambret, 2012* 42 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2012* 43 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, 2012* 44 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2012* 45 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Basel, 2012* 46 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2012* 47 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Penn State University, 2012* 48 Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2012* 49 List of Figures Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Zone (%), 2012* 7 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 8 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 9 Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2012* 10 Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2012* 11 Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries (%), 2012* 12 Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2012* 13 Rhabdomyosarcoma Therapeutics Clinical Trials, G7 Countries (%), 2012* 15 Rhabdomyosarcoma Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 16 Rhabdomyosarcoma Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 18 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Phase (%), 2012* 19 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012* 20 Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 21 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010 23 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 24 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 26 Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 27 GlobalData Methodology 117 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
